Metabolic shifts induced by fatty acid synthase inhibitor orlistat in non-small cell lung carcinoma cells provide novel pharmacodynamic biomarkers for positron emission tomography and magnetic resonance spectroscopy

Molecular Imaging and Biology

Volumn 15, Issue 2, 2013, Pages 136-147

  Sankaranarayanapillai, Madhuri ^a   Zhang, Nianxiang ^a   Baggerly, Keith A ^a   Gelovani, Juri G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Biomarkers; FASN; Metabolic changes; MRS; Orlistat

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID SYNTHASE; KETONE; TETRAHYDROLIPSTATIN;

ARTICLE; CANCER CELL CULTURE; CELL METABOLISM; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MECHANISM; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84878505225     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0587-6     Document Type: Article

References (31)

1. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7(10):763-777
2. Mashima T, Seimiya H, Tsuruo T (2009) De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 100(9):1369-1372
3. Kuhajda FP (2000) Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16(3):202-208
4. Menendez JA, Lupu R (2004) Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp (Warsz) 52(6):414-426
5. Orita H et al (2007) Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res 13(23):7139-7145
6. Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ (2007) Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 67(3):1262-1269
7. Zadra G, Priolo C, Patnaik A, Loda M (2010) New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res 16(13):3322-3328
8. Jin Q et al (2010) Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res 12(6):R96
9. Woodworth HL et al (2010) Dietary fish oil alters T lymphocyte cell populations and exacerbates disease in a mouse model of inflammatory colitis. Cancer Res 70(20):7960-7969
10. Ross J et al (2008) Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol Cancer Ther 7(8):2556-2565
11. Yeh HH et al (2011) Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A 108(4):1603-1608
12. Tyagi RK, Azrad A, Degani H, Salomon Y (1996) Simultaneous extraction of cellular lipids and water-soluble metabolites: evaluation by NMR spectroscopy. Magn Reson Med 35(2):194-200
13. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64(6):2070-2075
14. Lee JS et al (2007) FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer. Pharm Res 24(6):1202-1207
15. 11C- Acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 49(2):327-334
16. Yun M et al (2009) The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma. J Nucl Med 50(8):1222-1228
17. Haberkorn U et al (1994) FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 21(6):827-834
18. de Geus-Oei LF et al (2007) Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 55(1):79-87
19. Jadvar H, Alavi A, Gambhir SS (2009) 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 50(11):1820-1827
20. Ana M Abrantes MM, Ana C Gonçalves, Maria C Rodrigues, Ana C Mamede, & Sónia D Tavares JML, Adriano Rodrigues, Ana B Sarmento-Ribeiro, Maria F Botelho (2010) GLUT expression and 18F-FDG uptake in breast cancer cell lines. BMC Proceedings pP21
21. Sharma RI, Welch AE, Schweiger L, Craib S, Smith TAD (2011) [18F]Fluoro-2-deoxy-d-glucose incorporation by MCF-7 breast tumour cells in vitro is modulated by treatment with tamoxifen, doxorubicin, and docetaxel: relationship to chemotherapy-induced changes in ATP content, hexokinase activity, and glucose transport. Int J Mol Imaging 2011:1-8
22. Nosho K et al (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10(6):534-541
23. Fruman DA, Edinger AL (2008) Cancer therapy: staying current with AMPK. Biochem J 412(2):e3-5
24. Pradelli LA et al (2010) Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 29(11):1641-1652
25. Knowles LM, Smith JW (2007) Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer. BMC Genomics 8:168
26. Menendez JA, Vellon L, Lupu R (2005) Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 16(8):1253-1267
27. Claycombe KJ et al (1998) Insulin increases fatty acid synthase gene transcription in human adipocytes. Am J Physiol 274(5 Pt 2):R1253-1259
28. Fernandez-Real JM et al (2010) Extracellular fatty acid synthase: a possible surrogate biomarker of insulin resistance. Diabetes 59(6):1506-1511
29. Liu H, Liu JY, Wu X, Zhang JT (2010) Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol 1(1):69-89
30. Yamasaki M, Hasegawa S, Kitani T, Hidai K, Fukui T (2007) Differential effects of obesity on acetoacetyl-CoA synthetase gene in rat adipose tissues. Eur J Lipid Sci Technol 109(6):617-622
31. Zhou W et al (2007) Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 67(7):2964-2971